{"schema_version":"secwatch.filing_event.v1","accession":"0001708599-25-000016","form_type":"8-K","ticker":"SER","cik":"0001708599","company_name":"Serina Therapeutics, Inc.","filed_at":"2025-02-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.529494+00:00","generated_at":"2026-05-26T22:55:59.343959+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Serina Therapeutics appoints Dr. Jay Venkatesan to board; Dr. Milton Harris becomes Director Emeritus","bullets":["Dr. Jay Venkatesan appointed to Board effective Feb 12, 2025; will serve as Audit Committee Chair and on Nominating/Governance Committee.","Venkatesan previously co-founded Alpine Immune Sciences (acquired by Vertex for $4.9B) and served as CEO of Angion Biomedica.","Dr. Milton Harris departs board effective Feb 11, 2025, becomes Director Emeritus and Chair of Scientific Advisory Board.","Harris is co-founder, instrumental in POZ Platform; departure not due to any disagreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001708599-25-000016","json":"https://secwatch.observer/filing/0001708599-25-000016.json","markdown":"https://secwatch.observer/filing/0001708599-25-000016.md","text":"https://secwatch.observer/filing/0001708599-25-000016.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708599/000170859925000016/0001708599-25-000016-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708599/000170859925000016/ser-20250211.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T22:55:59.343959+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"05565eac11","claim":"Dr. Jay Venkatesan was appointed as Director at Serina Therapeutics, Inc..","evidence_excerpt":"On February 11, 2025 , the Board of Directors of Serina Therapeutics, Inc. (the “Company”) appointed Dr. Jay Venkatesan to the Company’s Board of Directors, effective February 12, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708599/000170859925000016/0001708599-25-000016-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"6a5a3b2af4","claim":"Dr. Milton Harris departed as Director at Serina Therapeutics, Inc..","evidence_excerpt":"The Company also announced the departure of Dr. Milton Harris from its Board of Directors effective February 11, 2025 .","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708599/000170859925000016/0001708599-25-000016-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"departed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}